A few weeks ago we looked at Canadian cannabis company Ayurcann (AYURF) and how it was poised to capitalize on a growing market for legal cannabis via its business lines in white labeling, oil extraction and refinement, bulk oil sales, packaging solutions, and medical cannabis products. The original article outlined how Ayurcann was in a good position to stake a leadership claim in a potentially explosive growth market, and recently some additional catalysts have come to light. The recent industry-wide sell-off is presenting investors with an opportunity to pick up shares of an industry leader at a discount.
In the company’s most recent updates, several strategic initiatives were highlighted, including news that the company’s products are now available in more than 1,000 locations across Canada. In the vape segment, the company’s Fuego brand is consistently ranked in the top 5 brands in sales and is now available country-wide.
Twelve new SKUs have recently been accepted by provincial governance boards across several product lines including vapes, tinctures, flowers, and pre-rolls with shipping expected to begin in July of 2022. Tinctures look to be an area poised for breakout growth, and Ayurcann’s Joints brand is well-positioned to grab market share. Joints branded tinctures come in 15, 30, and 60 mL sizes, offering consumers excellent value for their money in the high potency CBD space.
Another positive development is the recent announcement that the company received a license from Health Canada to sell dried cannabis flowers through authorized distributors and retailers throughout Canada. This license should allow Ayurcann to pursue higher-margin opportunities and increase market share in Canada. Dried flowers are a high-growth segment within the cannabis market and Ayurcann now can meet market demand via national distribution. The dried flower products round out the company’s product portfolio and Ayurcann is now able to offer consumers a cannabis solution for any vehicle they desire.
Back in May Ayurcann reported its most recent quarterly results highlighted by revenue of $2.8 million, which was up from $2.6 million over the same period in 2021. The company realized a profit of $580,000 for the quarter as it establishes itself as one of the major dominant players in a rapidly growing industry. Canada was the first large developed nations to legalize both recreational and medicinal cannabis so the industry as a whole is in the very early stages. Ayurcann, as we have highlighted before, and now as their quarterly results demonstrate, is poised to be one of the future titans of this young and growing industry.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated one thousand dollars cash for the creation and dissemination of this content by a third party Guerrilla Capital and Ryan Yanch.
This material does not represent a solicitation to buy or sell any securities. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
